PriceTargets.com logo

Moderna - MRNA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $84.00
  • Forecasted Upside: 127.40%
  • Number of Analysts: 22
  • Breakdown:
  • 3 Sell Ratings
  • 13 Hold Ratings
  • 5 Buy Ratings
  • 1 Strong Buy Ratings
$36.94 As of 11/20/2024 01:00 AM ET
▼ -0.35 (-0.94%)

This chart shows the closing price for MRNA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Moderna Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MRNA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MRNA

Analyst Price Target is $84.00
▲ +127.40% Upside Potential
This price target is based on 22 analysts offering 12 month price targets for Moderna in the last 3 months. The average price target is $84.00, with a high forecast of $179.00 and a low forecast of $40.00. The average price target represents a 127.40% upside from the last price of $36.94.

This chart shows the closing price for MRNA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 22 contributing investment analysts is to hold stock in Moderna. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 5 hold ratings
  • 2 sell ratings
Ratings as of
5/31/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 9 hold ratings
  • 3 sell ratings
Ratings as of
8/29/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 9 hold ratings
  • 3 sell ratings
Ratings as of
11/27/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 9 hold ratings
  • 1 sell ratings
Ratings as of
2/25/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 9 hold ratings
  • 2 sell ratings
Ratings as of
5/25/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 8 hold ratings
  • 1 sell ratings
Ratings as of
8/23/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 14 hold ratings
  • 2 sell ratings
Ratings as of
10/22/2024
  • 1 strong buy ratings
  • 5 buy ratings
  • 13 hold ratings
  • 3 sell ratings
Ratings as of
11/21/2024

Latest Recommendations

  • 1 strong buy ratings
  • 5 buy ratings
  • 13 hold ratings
  • 3 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/19/2024Berenberg BankInitiated CoverageHold$42.00
11/18/2024Hsbc Global ResUpgradeHold ➝ Strong-Buy
11/18/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$115.00 ➝ $69.00
11/18/2024HSBCUpgradeHold ➝ Buy$58.00
11/15/2024Wolfe ResearchInitiated CoverageUnderperform$40.00
11/8/2024BarclaysLower TargetOverweight ➝ Overweight$125.00 ➝ $111.00
11/8/2024Needham & Company LLCReiterated RatingHold
11/4/2024JPMorgan Chase & Co.Lower TargetUnderweight ➝ Underweight$70.00 ➝ $59.00
10/24/2024UBS GroupLower TargetBuy ➝ Buy$140.00 ➝ $108.00
10/17/2024Sanford C. BernsteinInitiated CoverageMarket Perform$55.00
10/15/2024Jefferies Financial GroupLower TargetHold ➝ Hold$65.00 ➝ $55.00
9/19/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$75.00 ➝ $75.00
9/17/2024Leerink PartnersLower TargetUnderperform ➝ Underperform$60.00 ➝ $48.00
9/16/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$178.00 ➝ $139.00
9/16/2024BarclaysLower TargetOverweight ➝ Overweight$155.00 ➝ $125.00
9/13/2024Bank of AmericaLower TargetNeutral ➝ Neutral$130.00 ➝ $110.00
9/13/2024TD CowenLower TargetHold ➝ Hold$70.00 ➝ $60.00
9/13/2024Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$90.00 ➝ $75.00
9/13/2024Needham & Company LLCReiterated RatingHold
9/13/2024Piper SandlerLower TargetOverweight ➝ Overweight$157.00 ➝ $115.00
9/13/2024Jefferies Financial GroupDowngradeBuy ➝ Hold$120.00 ➝ $65.00
9/13/2024JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$88.00 ➝ $70.00
9/13/2024OppenheimerDowngradeOutperform ➝ Market Perform
8/28/2024Hsbc Global ResUpgradeModerate Sell ➝ Hold
8/28/2024HSBCUpgradeReduce ➝ Hold$82.00
8/15/2024JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$96.00 ➝ $88.00
8/7/2024Deutsche Bank AktiengesellschaftUpgradeSell ➝ Hold$85.00 ➝ $80.00
8/5/2024Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$125.00 ➝ $90.00
8/2/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$160.00 ➝ $125.00
8/2/2024The Goldman Sachs GroupLower TargetBuy ➝ Buy$204.00 ➝ $178.00
8/2/2024BarclaysLower TargetOverweight ➝ Overweight$168.00 ➝ $155.00
8/2/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$214.00 ➝ $157.00
8/1/2024Needham & Company LLCReiterated RatingHold
6/28/2024Needham & Company LLCReiterated RatingHold
6/27/2024William BlairReiterated RatingMarket Perform
6/27/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$214.00 ➝ $214.00
6/27/2024Evercore ISIReiterated RatingIn-Line ➝ In-Line$120.00 ➝ $120.00
6/12/2024OppenheimerBoost TargetOutperform ➝ Outperform$163.00 ➝ $179.00
6/3/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$135.00 ➝ $160.00
6/3/2024Needham & Company LLCReiterated RatingHold
5/14/2024Evercore ISIInitiated CoverageIn-Line$120.00
5/13/2024Evercore ISIUpgradeHold
5/7/2024UBS GroupBoost TargetBuy ➝ Buy$143.00 ➝ $151.00
5/3/2024Canaccord Genuity GroupBoost TargetHold ➝ Hold$91.00 ➝ $106.00
5/3/2024Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$125.00 ➝ $135.00
5/3/2024OppenheimerBoost TargetOutperform ➝ Outperform$142.00 ➝ $163.00
5/2/2024Needham & Company LLCReiterated RatingHold
4/11/2024Needham & Company LLCReiterated RatingHold
4/9/2024Jefferies Financial GroupReiterated RatingBuy ➝ Buy$125.00
4/1/2024William BlairReiterated RatingMarket Perform
3/28/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$125.00
3/28/2024Needham & Company LLCReiterated RatingHold
2/26/2024HSBCReiterated RatingHold ➝ Reduce$75.00 ➝ $86.00
2/23/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$125.00
2/23/2024Canaccord Genuity GroupBoost TargetHold ➝ Hold$82.00 ➝ $91.00
1/12/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$125.00
1/2/2024OppenheimerUpgradeMarket Perform ➝ Outperform$142.00
12/1/2023JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$93.00 ➝ $90.00
11/29/2023Canaccord Genuity GroupInitiated CoverageHold$82.00
11/29/2023Canaccord Genuity GroupInitiated CoverageHold$82.00
11/3/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$180.00 ➝ $125.00
11/3/2023The Goldman Sachs GroupLower TargetBuy ➝ Buy$269.00 ➝ $231.00
11/3/2023HSBCUpgradeReduce ➝ Hold$89.00 ➝ $69.00
11/2/2023Deutsche Bank AktiengesellschaftDowngradeHold ➝ Sell$125.00 ➝ $60.00
9/13/2023ArgusLower TargetBuy ➝ Buy$160.00 ➝ $140.00
8/4/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$128.00 ➝ $123.00
8/4/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$200.00 ➝ $190.00
8/4/2023Jefferies Financial GroupLower Target$275.00 ➝ $175.00
8/4/2023Bank of AmericaLower TargetNeutral ➝ Neutral$175.00 ➝ $150.00
8/4/2023TD CowenDowngradeOutperform ➝ Market Perform$145.00 ➝ $125.00
8/3/2023Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$200.00 ➝ $125.00
7/24/2023TD CowenLower TargetOutperform$175.00 ➝ $165.00
7/24/2023William BlairInitiated CoverageMarket Perform$136.28
7/14/2023HSBCInitiated CoverageReduce$97.00
6/26/202351jobReiterated RatingUpgrade
6/26/2023UBS GroupUpgradeNeutral ➝ Buy$221.00 ➝ $191.00
5/5/2023Morgan StanleyLower Target$185.00 ➝ $153.00
4/25/2023GuggenheimInitiated CoverageNeutral
4/10/2023JPMorgan Chase & Co.Boost TargetNeutral$127.00 ➝ $145.00
3/13/2023TD CowenUpgradeMarket Perform ➝ Outperform$150.00 ➝ $180.00
3/1/2023Royal Bank of CanadaInitiated CoverageOutperform$200.00
2/28/2023Deutsche Bank AktiengesellschaftLower TargetBuy$225.00 ➝ $200.00
2/24/2023Leerink PartnersDowngradeMarket Perform ➝ Underperform$111.00 ➝ $93.00
2/24/2023SVB SecuritiesDowngradeMarket Perform ➝ Underperform$111.00 ➝ $93.00
2/23/2023Morgan StanleyLower Target$205.00 ➝ $185.00
2/8/2023JPMorgan Chase & Co.Boost TargetNeutral$132.00 ➝ $138.00
1/25/2023CowenBoost TargetMarket Perform$130.00 ➝ $150.00
1/24/2023Morgan StanleyLower TargetEqual Weight$209.00 ➝ $205.00
1/18/2023Leerink PartnersBoost TargetMarket Perform$102.00 ➝ $111.00
1/18/2023Chardan CapitalBoost TargetNeutral$191.00 ➝ $208.00
1/11/2023Deutsche Bank AktiengesellschaftBoost Target$185.00 ➝ $225.00
12/20/2022Piper SandlerBoost TargetOverweight$214.00 ➝ $217.00
12/19/2022Jefferies Financial GroupUpgradeHold ➝ Buy$170.00 ➝ $275.00
12/16/2022Morgan StanleyBoost TargetEqual Weight$170.00 ➝ $209.00
12/14/2022Chardan CapitalDowngradeBuy ➝ Neutral$186.00 ➝ $191.00
12/13/2022Leerink PartnersBoost TargetMarket Perform$101.00 ➝ $102.00
11/15/2022Bank of AmericaBoost Target$160.00 ➝ $182.00
11/7/2022Chardan CapitalLower TargetBuy$188.00 ➝ $186.00
11/4/2022Morgan StanleyLower TargetEqual Weight$175.00 ➝ $170.00
10/24/2022JPMorgan Chase & Co.Lower TargetNeutral$165.00 ➝ $122.00
10/21/2022Leerink PartnersUpgradeUnderperform ➝ Market Perform$174.00 ➝ $101.00
10/20/2022CowenLower Target$165.00 ➝ $145.00
10/20/2022CowenLower Target$165.00 ➝ $145.00
10/18/2022Morgan StanleyLower TargetEqual Weight$197.00 ➝ $175.00
10/13/2022The Goldman Sachs GroupBoost TargetBuy$290.00 ➝ $296.00
9/14/2022ArgusLower TargetBuy$180.00 ➝ $150.00
9/7/2022Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$155.00 ➝ $165.00
8/4/2022Morgan StanleyLower TargetEqual Weight$199.00 ➝ $197.00
8/1/2022Leerink PartnersBoost TargetUnderperform$70.00 ➝ $77.00
6/7/2022Leerink PartnersLower TargetUnderperform$80.00 ➝ $70.00
5/17/2022Piper SandlerLower TargetOverweight$348.00 ➝ $214.00
4/12/2022Morgan StanleyBoost TargetEqual Weight$205.00 ➝ $217.00
3/25/2022Leerink PartnersLower TargetUnderperform$81.00 ➝ $80.00
3/7/2022Deutsche Bank AktiengesellschaftLower TargetHold$175.00 ➝ $155.00
2/28/2022Morgan StanleyLower TargetEqual Weight$213.00 ➝ $205.00
2/25/2022Jefferies Financial GroupLower Target$200.00 ➝ $170.00
2/25/2022BarclaysLower Target$404.00 ➝ $210.00
2/25/2022Leerink PartnersLower TargetUnderperform$85.00 ➝ $81.00
2/1/2022Morgan StanleyLower TargetEqual Weight$315.00 ➝ $213.00
2/1/2022Redburn PartnersUpgradeSell ➝ Neutral
1/28/2022Leerink PartnersLower TargetUnderperform$86.00 ➝ $85.00
1/26/2022Deutsche Bank AktiengesellschaftUpgradeSell ➝ Hold$175.00
1/21/2022UBS GroupInitiated CoverageNeutral$221.00
1/21/2022Bank of AmericaUpgradeUnderperform ➝ Neutral$135.00 ➝ $180.00
1/18/2022Morgan StanleyBoost TargetEqual Weight$313.00 ➝ $315.00
1/6/2022ArgusLower Target$420.00 ➝ $350.00
12/23/2021Leerink PartnersReiterated RatingSell
12/6/2021CowenInitiated CoverageMarket Perform$250.00
11/8/2021Wolfe ResearchInitiated CoverageOutperform$304.00
11/5/2021Leerink PartnersBoost TargetUnderperform$85.00 ➝ $86.00
11/5/2021Morgan StanleyLower TargetEqual Weight$337.00 ➝ $313.00
11/5/2021Jefferies Financial GroupLower TargetHold$375.00 ➝ $325.00
11/5/2021The Goldman Sachs GroupReiterated RatingBuy$395.00
11/5/2021Piper SandlerLower TargetOverweight$348.00
10/22/2021Deutsche Bank AktiengesellschaftInitiated CoverageSell$250.00
10/15/2021Piper SandlerUpgradeNeutral ➝ Overweight
9/12/2021Leerink PartnersReiterated RatingSell
9/7/2021Morgan StanleyBoost TargetEqual Weight$190.00 ➝ $337.00
8/6/2021Piper SandlerDowngradeOverweight ➝ Neutral
8/5/2021OppenheimerDowngradeOutperform ➝ Market Perform
7/15/2021Jefferies Financial GroupBoost TargetPositive ➝ Hold$170.00 ➝ $250.00
7/7/2021Chardan CapitalReiterated RatingBuy
6/24/2021ArgusBoost TargetBuy$200.00 ➝ $230.00
5/7/2021Chardan CapitalBoost TargetBuy$182.00 ➝ $188.00
5/7/2021Morgan StanleyLower TargetEqual Weight$201.00 ➝ $190.00
5/7/2021BarclaysBoost TargetOverweight$178.00 ➝ $194.00
5/7/2021The Goldman Sachs GroupBoost TargetBuy$206.00 ➝ $228.00
5/6/2021Piper SandlerLower TargetOverweight$234.00 ➝ $231.00
5/5/2021Jefferies Financial GroupReiterated RatingHold
4/21/2021Piper SandlerReiterated RatingOverweight$208.00 ➝ $234.00
4/18/2021Leerink PartnersReiterated RatingSell
4/16/2021Needham & Company LLCReiterated RatingHold
4/15/2021Piper SandlerBoost TargetOverweight$208.00 ➝ $234.00
3/15/2021Piper SandlerReiterated RatingOverweight$208.00
3/1/2021Chardan CapitalBoost TargetPositive ➝ Buy$107.00 ➝ $182.00
2/26/2021BarclaysBoost Target$169.00 ➝ $178.00
2/26/2021Brookline Capital ManagementBoost TargetBuy$180.00 ➝ $205.00
2/26/2021Bank of AmericaReiterated RatingSell$140.00
2/25/2021Morgan StanleyLower TargetEqual Weight$215.00 ➝ $201.00
2/18/2021Jefferies Financial GroupBoost Target$150.00 ➝ $180.00
2/18/2021Morgan StanleyBoost TargetEqual Weight$150.00 ➝ $215.00
2/17/2021Piper SandlerBoost Target$170.00 ➝ $208.00
2/1/2021OppenheimerBoost TargetOutperform$178.00 ➝ $206.00
2/1/2021Wells Fargo & CompanyBoost TargetOverweight ➝ Equal Weight$129.00 ➝ $145.00
2/1/2021Leerink PartnersBoost TargetUnderperform$69.00 ➝ $80.00
2/1/2021Bank of AmericaDowngradeNeutral ➝ Underperform$150.00
1/22/2021Bank of AmericaBoost TargetNeutral$130.00 ➝ $140.00
1/6/2021Piper SandlerReiterated RatingOverweight$166.00 ➝ $170.00
12/21/2020Leerink PartnersBoost TargetPositive ➝ Underperform$60.00 ➝ $69.00
12/21/2020OppenheimerBoost TargetOutperform$157.00 ➝ $178.00
12/18/2020BarclaysBoost TargetOverweight$84.00 ➝ $169.00
12/16/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$100.00 ➝ $150.00
12/15/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$90.00 ➝ $150.00
12/11/2020The Goldman Sachs GroupReiterated RatingBuy$139.00
12/9/2020Needham & Company LLCDowngradeBuy ➝ Hold
12/3/2020Bank of AmericaBoost Target$105.00 ➝ $150.00
12/1/2020ArgusBoost TargetHold ➝ Buy$88.00 ➝ $200.00
11/30/2020Wells Fargo & CompanyBoost TargetEqual Weight$92.00 ➝ $129.00
11/25/2020The Goldman Sachs GroupBoost Target$107.00 ➝ $139.00
11/24/2020Leerink PartnersBoost TargetUnderperform$59.00 ➝ $60.00
11/23/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$92.00
11/17/2020Redburn PartnersInitiated CoverageSell
11/17/2020BMO Capital MarketsDowngradeOutperform ➝ Market Perform$109.00
11/16/2020Chardan CapitalBoost TargetPositive ➝ Buy$93.00 ➝ $107.00
11/16/2020OppenheimerBoost TargetOutperform$108.00 ➝ $157.00
11/16/2020Piper SandlerBoost TargetOverweight$136.00 ➝ $166.00
11/11/2020ArgusBoost TargetBuy$80.00 ➝ $88.00
11/11/2020Morgan StanleyBoost TargetOverweight$90.00 ➝ $100.00
10/8/2020Chardan CapitalLower TargetBuy$95.00 ➝ $93.00
9/24/2020Leerink PartnersReiterated RatingSell$41.00
9/8/2020Leerink PartnersDowngradeMarket Perform ➝ Underperform$58.00 ➝ $41.00
8/12/2020Jefferies Financial GroupReiterated RatingBuy$90.00
8/12/2020OppenheimerReiterated RatingBuy$108.00
8/12/2020Leerink PartnersLower TargetMarket Perform$60.00 ➝ $58.00
8/12/2020Chardan CapitalReiterated RatingBuy$95.00
8/6/2020Chardan CapitalReiterated RatingBuy$95.00
8/6/2020Leerink PartnersLower TargetMarket Perform$65.00 ➝ $60.00
8/6/2020JPMorgan Chase & Co.Reiterated RatingHold
8/5/2020Needham & Company LLCInitiated CoverageBuy$94.00
7/27/2020Chardan CapitalReiterated RatingBuy$95.00
7/27/2020SunTrust BanksInitiated CoverageBuy$120.00
7/27/2020The Goldman Sachs GroupSet TargetBuy$105.00
7/27/2020BMO Capital MarketsBoost TargetOutperform$94.00 ➝ $112.00
7/24/2020OppenheimerInitiated CoverageBuy$108.00
7/23/2020Leerink PartnersInitiated CoverageMarket Perform$65.00
7/20/2020JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$60.00 ➝ $89.00
7/15/2020Needham & Company LLCInitiated CoverageBuy$94.00
7/15/2020OppenheimerInitiated CoverageBuy$108.00
7/15/2020Piper SandlerBoost Target$100.00 ➝ $134.00
7/15/2020Chardan CapitalBoost TargetBuy$84.00 ➝ $95.00
7/13/2020Brookline Capital ManagementReiterated RatingBuy$95.00
7/13/2020Jefferies Financial GroupInitiated CoverageBuy$90.00
6/30/2020ArgusInitiated CoverageBuy$80.00
6/25/2020Chardan CapitalReiterated RatingBuy$84.00
6/12/2020Chardan CapitalReiterated RatingBuy$84.00
6/11/2020Needham & Company LLCReiterated RatingBuy$94.00
6/8/2020BarclaysInitiated CoverageOverweight$68.00
6/3/2020Bank of AmericaLower Target$80.00 ➝ $75.00
6/2/2020OppenheimerReiterated RatingBuy$108.00
5/30/2020Chardan CapitalReiterated RatingBuy$52.00
5/20/2020Morgan StanleyBoost TargetOverweight$37.00 ➝ $90.00
5/19/2020Bank of AmericaBoost TargetNeutral$70.00 ➝ $95.00
5/19/2020BMO Capital MarketsBoost TargetOutperform$83.00 ➝ $112.00
5/18/2020Needham & Company LLCInitiated CoverageBuy$94.00
5/18/2020OppenheimerBoost TargetOutperform$62.00 ➝ $108.00
5/18/2020Piper SandlerBoost TargetOverweight$57.00 ➝ $102.00
5/18/2020The Goldman Sachs GroupBoost TargetBuy$63.00 ➝ $105.00
5/12/2020JPMorgan Chase & Co.Reiterated RatingBuy$60.00
5/11/2020Roth CapitalBoost TargetBuy$41.00 ➝ $68.00
5/8/2020OppenheimerBoost TargetOutperform$43.00 ➝ $62.00
5/7/2020Needham & Company LLCBoost TargetBuy$35.00 ➝ $58.00
5/1/2020Piper SandlerReiterated RatingBuy$57.00
4/30/2020BMO Capital MarketsInitiated CoverageOutperform$83.00
4/29/2020BMO Capital MarketsInitiated CoverageOutperform
4/28/2020Chardan CapitalBoost TargetBuy$40.00 ➝ $52.00
4/21/2020OppenheimerInitiated CoverageBuy$43.00
4/17/2020JPMorgan Chase & Co.Reiterated RatingBuy
4/17/2020Piper SandlerBoost Target$34.00 ➝ $57.00
4/16/2020Roth CapitalBoost Target$33.00 ➝ $41.00
4/15/2020Morgan StanleyBoost TargetOverweight$30.00 ➝ $37.00
4/15/2020Chardan CapitalReiterated RatingBuy$40.00
4/15/2020OppenheimerBoost TargetOutperform$31.00 ➝ $43.00
4/14/2020Piper SandlerReiterated RatingBuy
3/30/2020Piper SandlerReiterated RatingBuy$34.00
3/24/2020Needham & Company LLCReiterated RatingBuy$35.00
3/16/2020Piper SandlerReiterated RatingBuy$32.00
3/16/2020Chardan CapitalReiterated RatingBuy$40.00
3/5/2020Chardan CapitalReiterated RatingBuy$40.00
3/5/2020Bank of AmericaDowngradeBuy ➝ Neutral$32.00
2/27/2020Roth CapitalBoost Target$24.00 ➝ $33.00
2/26/2020Needham & Company LLCBoost TargetBuy$28.00 ➝ $35.00
2/25/2020Piper SandlerReiterated RatingBuy$32.00
2/25/2020Chardan CapitalReiterated RatingBuy$40.00
2/11/2020Chardan CapitalReiterated RatingBuy$40.00
1/22/2020Piper SandlerReiterated RatingBuy$32.00
1/14/2020JPMorgan Chase & Co.Reiterated RatingBuy
1/10/2020Chardan CapitalReiterated RatingBuy$40.00
1/2/2020OppenheimerDowngradeOutperform$27.00
1/2/2020Morgan StanleyInitiated CoverageOverweight$29.00
1/2/2020BarclaysInitiated CoverageOverweight$20.00
1/2/2020Bank of AmericaInitiated CoverageBuy$20.00
1/2/2020JPMorgan Chase & Co.Initiated CoverageOverweight$22.00
1/2/2020Needham & Company LLCInitiated CoverageBuy$28.00
1/2/2020The Goldman Sachs GroupInitiated CoverageBuy$25.00
1/2/2020Piper Sandler CompaniesInitiated CoverageOverweight$24.00
12/3/2019Bank of AmericaReiterated RatingBuy$29.00
12/3/2019Bank of AmericaInitiated CoverageBuy$29.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.44 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 41 very positive mentions
  • 46 positive mentions
  • 19 negative mentions
  • 3 very negative mentions
Mentions as of
4/24/2024
  • 45 very positive mentions
  • 52 positive mentions
  • 10 negative mentions
  • 6 very negative mentions
Mentions as of
5/24/2024
  • 55 very positive mentions
  • 22 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
6/23/2024
  • 30 very positive mentions
  • 25 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
Mentions as of
7/23/2024
  • 26 very positive mentions
  • 73 positive mentions
  • 19 negative mentions
  • 2 very negative mentions
Mentions as of
8/22/2024
  • 45 very positive mentions
  • 95 positive mentions
  • 23 negative mentions
  • 2 very negative mentions
Mentions as of
9/21/2024
  • 31 very positive mentions
  • 53 positive mentions
  • 10 negative mentions
  • 4 very negative mentions
Mentions as of
10/21/2024
  • 32 very positive mentions
  • 54 positive mentions
  • 14 negative mentions
  • 3 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 32 very positive mentions
  • 54 positive mentions
  • 14 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Moderna logo
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $36.94
Low: $36.41
High: $38.22

50 Day Range

MA: $56.98
Low: $36.85
High: $79.51

52 Week Range

Now: $36.94
Low: $35.80
High: $170.47

Volume

7,295,775 shs

Average Volume

4,782,457 shs

Market Capitalization

$14.22 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.69

Frequently Asked Questions

What sell-side analysts currently cover shares of Moderna?

The following Wall Street analysts have issued stock ratings on Moderna in the last twelve months: Bank of America Co., Barclays PLC, Berenberg Bank, Canaccord Genuity Group Inc., Deutsche Bank Aktiengesellschaft, Evercore ISI, Hsbc Global Res, HSBC Holdings plc, Jefferies Financial Group Inc., JPMorgan Chase & Co., Leerink Partners, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Royal Bank of Canada, Sanford C. Bernstein, TD Cowen, The Goldman Sachs Group, Inc., UBS Group AG, William Blair, and Wolfe Research.
View the latest analyst ratings for MRNA.

What is the current price target for Moderna?

0 Wall Street analysts have set twelve-month price targets for Moderna in the last year. Their average twelve-month price target is $84.00, suggesting a possible upside of 127.4%. Oppenheimer Holdings Inc. has the highest price target set, predicting MRNA will reach $179.00 in the next twelve months. Wolfe Research has the lowest price target set, forecasting a price of $40.00 for Moderna in the next year.
View the latest price targets for MRNA.

What is the current consensus analyst rating for Moderna?

Moderna currently has 3 sell ratings, 13 hold ratings, 5 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MRNA, but not buy more shares or sell existing shares.
View the latest ratings for MRNA.

What other companies compete with Moderna?

Other companies that are similar to Moderna include Neurocrine Biosciences, Bio-Techne, Repligen, Biogen and CRISPR Therapeutics. Learn More about companies similar to Moderna.

How do I contact Moderna's investor relations team?

Moderna's physical mailing address is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The company's listed phone number is (617) 714-6500 and its investor relations email address is [email protected]. The official website for Moderna is www.modernatx.com. Learn More about contacing Moderna investor relations.